TrialNature communications2026

First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial.

Sylvie Lorenzen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.